Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPA and Radiotherapy for Stage IE/IIE Natural Killer/T-cell Lymphoma
NCT04366128Completed
- Start
- Apr 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab, Rivoceranib and pegaspargase in Extranodal NK/T-cell lymphoma (ENKTL). Primary endpoint: Complete Response Rate at 24 weeks. Started Apr 2020; status: completed.
02
Drugs
camrelizumabRivoceranibpegaspargase
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04366128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366128.